SG11201803913RA - Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain - Google Patents
Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of painInfo
- Publication number
- SG11201803913RA SG11201803913RA SG11201803913RA SG11201803913RA SG11201803913RA SG 11201803913R A SG11201803913R A SG 11201803913RA SG 11201803913R A SG11201803913R A SG 11201803913RA SG 11201803913R A SG11201803913R A SG 11201803913RA SG 11201803913R A SG11201803913R A SG 11201803913RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- opioid
- oxide derivative
- pct
- cambridgeshire
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1520390.4A GB201520390D0 (en) | 2015-11-19 | 2015-11-19 | Composition |
| PCT/GB2016/053600 WO2017085502A1 (en) | 2015-11-19 | 2016-11-18 | Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803913RA true SG11201803913RA (en) | 2018-06-28 |
Family
ID=55133015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803913RA SG11201803913RA (en) | 2015-11-19 | 2016-11-18 | Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180344726A1 (es) |
| EP (1) | EP3377048B1 (es) |
| JP (1) | JP2018534319A (es) |
| KR (1) | KR20180074797A (es) |
| CN (1) | CN108601747A (es) |
| AU (1) | AU2016355113A1 (es) |
| BR (1) | BR112018009886A2 (es) |
| CA (1) | CA3005775A1 (es) |
| ES (1) | ES2799516T3 (es) |
| GB (1) | GB201520390D0 (es) |
| IL (1) | IL259457A (es) |
| MX (1) | MX2018006157A (es) |
| SG (1) | SG11201803913RA (es) |
| WO (1) | WO2017085502A1 (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722928A (en) * | 1985-12-02 | 1988-02-02 | E. I. Du Pont De Nemours And Company | N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes |
| EP2092936B1 (en) * | 2000-02-08 | 2013-03-20 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
| GB0026137D0 (en) * | 2000-10-25 | 2000-12-13 | Euro Celtique Sa | Transdermal dosage form |
| US20040033253A1 (en) * | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
| US20040033255A1 (en) * | 2002-06-10 | 2004-02-19 | Baker Carl J. | Transdermal delivery device disposal system |
| NZ549576A (en) * | 2004-02-23 | 2010-04-30 | Euro Celtique Sa | Abuse resistance opioid transdermal delivery device using microspheres of opiate antagonist |
| JP2010510326A (ja) * | 2006-11-22 | 2010-04-02 | プロジェニックス ファーマスーティカルス インコーポレーテッド | ４，５−エポキシ−モルフィナニウム類似体のｎ−オキシド類 |
| WO2009067275A1 (en) * | 2007-11-21 | 2009-05-28 | Progenics Pharmaceuticals, Inc | N-oxides of 4,5-epoxy-morphinanium analogs |
| CA2718943A1 (en) * | 2008-03-26 | 2009-10-01 | Alltranz Inc. | Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists |
| WO2011009020A2 (en) * | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
| JP2013523780A (ja) * | 2010-04-02 | 2013-06-17 | オールトランツ インコーポレイティド | オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑止性経皮製剤 |
-
2015
- 2015-11-19 GB GBGB1520390.4A patent/GB201520390D0/en not_active Ceased
-
2016
- 2016-11-18 ES ES16801029T patent/ES2799516T3/es active Active
- 2016-11-18 SG SG11201803913RA patent/SG11201803913RA/en unknown
- 2016-11-18 MX MX2018006157A patent/MX2018006157A/es unknown
- 2016-11-18 CA CA3005775A patent/CA3005775A1/en not_active Abandoned
- 2016-11-18 CN CN201680067561.0A patent/CN108601747A/zh active Pending
- 2016-11-18 BR BR112018009886A patent/BR112018009886A2/pt not_active Application Discontinuation
- 2016-11-18 EP EP16801029.6A patent/EP3377048B1/en active Active
- 2016-11-18 US US15/777,333 patent/US20180344726A1/en not_active Abandoned
- 2016-11-18 KR KR1020187017271A patent/KR20180074797A/ko unknown
- 2016-11-18 JP JP2018526061A patent/JP2018534319A/ja active Pending
- 2016-11-18 AU AU2016355113A patent/AU2016355113A1/en not_active Abandoned
- 2016-11-18 WO PCT/GB2016/053600 patent/WO2017085502A1/en active Application Filing
-
2018
- 2018-05-17 IL IL259457A patent/IL259457A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018006157A (es) | 2019-04-04 |
| AU2016355113A1 (en) | 2018-05-24 |
| CA3005775A1 (en) | 2017-05-26 |
| IL259457A (en) | 2018-07-31 |
| WO2017085502A1 (en) | 2017-05-26 |
| ES2799516T3 (es) | 2020-12-18 |
| EP3377048B1 (en) | 2020-04-22 |
| GB201520390D0 (en) | 2016-01-06 |
| JP2018534319A (ja) | 2018-11-22 |
| CN108601747A (zh) | 2018-09-28 |
| US20180344726A1 (en) | 2018-12-06 |
| KR20180074797A (ko) | 2018-07-03 |
| EP3377048A1 (en) | 2018-09-26 |
| BR112018009886A2 (pt) | 2018-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201806485RA (en) | Pyrrolobenzodiazepine conjugates | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201408279QA (en) | Social sharing of security information in a group | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201806623VA (en) | Bacteria over-expressing c-di-amp and therapeutic methods | |
| SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones |